A randomized, double-blind, placebo-controlled, Phase 2 study evaluating efficacy and safety of inupadenant in combination with carboplatin and pemetrexed in adults with nonsquamous non-small cell lung cancer who have progressed on immunotherapy

Nonsquamous non-small cell lung cancer

Part 1 (Dose-Finding): Incidence of adverse events (AEs), serious adverse events (SAEs), dose-limiting toxicities (DLTs), AEs leading to dose-modifications or discontinuation, deaths, and clinically significant laboratory abnormalities., Part 2 (Randomized): Progression-free survival (PFS), defined as time from randomization to the date of first documented radiological progression using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 criteria or death due to any cause

Part 1: ORR; DoR; percent CTS from baseline; DCR, PFS, OS., Part 2: Incidence and frequency of AEs, SAEs, and AEs leading to dose modifications or discontinuation, deaths, and clinically significant laboratory abnormalities., Part 2: ORR; DoR; percent CTS from baseline; DCR; OS., Part 2: Time to definitive deterioration in global health status/quality of life (QoL), shortness of breath and pain per EORTC QLQ-C30 questionnaire. Please refer to Protocol for other secondary endpoints.

No related papers found yet.

Belgium, Czechia, France, Germany, Italy, Spain